Skip to Content
Merck
All Photos(1)

Documents

MAB8702

Sigma-Aldrich

Anti-Dengue Virus Type II Antibody, clone 3H5-1

clone 3H5-1, Chemicon®, from mouse

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

clone

3H5-1, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunofluorescence: suitable
inhibition assay: suitable (hemagglutination)

isotype

IgG1

shipped in

wet ice

General description

Dengue fever is an acute, mosquito-transmitted viral disease characterized by fever, headache, arthralgia (severe retro-orbital pain), myalgia, rash, nausea, and vomiting. Infections are caused by any of the four closely related, but antigenically distinct virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Infection with one of these serotypes does not provide cross-protective immunity, so persons living in a dengue-endemic area can have four dengue infections during their lifetimes. Dengue is primarily an urban disease of the tropics, and the viruses that cause it are maintained in a cycle that involves humans and Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on humans. Although most dengue infections result in relatively mild illness, some can produce Dengue Hemorrhagic Fever (DHF) or dengue shock syndrome, with children being particularly at risk. Although epidemic outbreaks have been reported since 1779, the incidence has been increasing, with global, multiple serotype pandemics intensifying within the last 15 years. There is no specific antiviral therapy for dengue, but for both classical dengue and dengue hemorrhagic fever, symptomatic and supportive measures are effective. Important risk factors for DHF include the strain and serotype of the virus involved, as well as the age, immune status, and genetic predisposition of the patient.

Specificity

Reacts with the Dengue type 2 virus.

Immunogen

Dengue type 2 antigen (New Guinea C).

Application

Recommended for use in an immunofluorescent assay. Also suitable for use in hemagglutination-inhibition tests and plaque-reduction assays.

IFA: 1:200-1:400.

Dilute with buffer pH 7.5-8.0 to desired working volumes. For extensive dilution, protein containing or other stabilizing medium should be used.

Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
This Anti-Dengue Virus Type II Antibody, clone 3H5-1 is validated for use in HI, IF for the detection of Dengue Virus Type II.

Physical form

Format: Purified
Protein G Purified
Protein G Purified immunoglobulin. Liquid in 0.02 M PB, 0.25 M NaCl, pH = 7.6 with 0.1% Na Azide as a preservative

Storage and Stability

Maintain at 2°C to 8°C in undiluted aliquots for up to 12 months after date of receipt.

Analysis Note

Control
Dengue positive patient sample

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Leticia Franco et al.
PLoS neglected tropical diseases, 5(8), e1251-e1251 (2011-08-11)
Dengue virus (DENV) circulates in human and sylvatic cycles. Sylvatic strains are both ecologically and evolutionarily distinct from endemic viruses. Although sylvatic dengue cycles occur in West African countries and Malaysia, only a few cases of mild human disease caused
Sialic acid expression in the mosquito Aedes aegypti and its possible role in dengue virus-vector interactions.
Cime-Castillo, J; Delannoy, P; Mendoza-Hernandez, G; Monroy-Martinez, V; Harduin-Lepers et al.
BioMed Research International null
Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking.
van der Schaar, HM; Rust, MJ; Waarts, BL; van der Ende-Metselaar, H; Kuhn, RJ; Wilschut et al.
Journal of virology null
Rodrigo Guabiraba et al.
European journal of immunology, 43(6), 1529-1544 (2013-03-19)
Dengue virus (DENV), a mosquito-borne flavivirus, is a public health problem in many tropical countries. IL-22 and IL-17A are key cytokines in several infectious and inflammatory diseases. We have assessed the contribution of IL-22 and IL-17A in the pathogenesis of
Jorge I Castañeda-Sánchez et al.
Intervirology, 59(1), 8-19 (2016-06-20)
The innate immune response is remarkably important for controlling infections. Information about the participation of antimicrobial peptides (AMPs) in response to dengue virus (DENV) is scarce. The aim of this study was to examine the AMP response to DENV-2 in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service